Invesco’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-21,023
| Closed | -$318K | – | 4099 |
|
|
2022
Q3 | $318K | Buy |
21,023
+1,946
| +10% | +$22.6K | ﹤0.01% | 3491 |
|
|
2022
Q2 | $143K | Sell |
19,077
-268
| -1% | -$1.89K | ﹤0.01% | 3815 |
|
|
2022
Q1 | $176K | Sell |
19,345
-73
| -0.4% | -$563 | ﹤0.01% | 3794 |
|
|
2021
Q4 | $137K | Sell |
19,418
-1,639
| -8% | -$17.1K | ﹤0.01% | 3854 |
|
|
2021
Q3 | $240K | Buy |
21,057
+3,256
| +18% | +$47.6K | ﹤0.01% | 3732 |
|
|
2021
Q2 | $285K | Buy |
+17,801
| New | +$305K | ﹤0.01% | 3650 |
|
|
2021
Q1 | – | Sell |
-17,197
| Closed | -$233K | – | 3975 |
|
|
2020
Q4 | $233K | Buy |
17,197
+5,313
| +45% | +$64.2K | ﹤0.01% | 3501 |
|
|
2020
Q3 | $140K | Sell |
11,884
-227
| -2% | -$2.77K | ﹤0.01% | 3538 |
|
|
2020
Q2 | $179K | Sell |
12,111
-1,093
| -8% | -$16.2K | ﹤0.01% | 3503 |
|
|
2020
Q1 | $179K | Sell |
13,204
-827,332
| -98% | -$15.7M | ﹤0.01% | 3443 |
|
|
2019
Q4 | $20.3M | Sell |
840,536
-43,010
| -5% | -$891K | 0.01% | 1419 |
|
|
2019
Q3 | $17M | Sell |
883,546
-27,641
| -3% | -$633K | ﹤0.01% | 1493 |
|
|
2019
Q2 | $26.9M | Sell |
911,187
-539,758
| -37% | -$20.8M | 0.01% | 1280 |
|
|
2019
Q1 | $68.9M | Buy |
1,450,945
+352,638
| +32% | +$15.5M | 0.02% | 688 |
|
|
2018
Q4 | $39.6M | Sell |
1,098,307
-274,567
| -20% | -$12.9M | 0.02% | 862 |
|
|
2018
Q3 | $84.5M | Buy |
1,372,874
+121,373
| +10% | +$7.8M | 0.03% | 622 |
|
|
2018
Q2 | $84.5M | Sell |
1,251,501
-37,534
| -3% | -$2.1M | 0.03% | 613 |
|
|
2018
Q1 | $69.9M | Buy |
1,289,035
+725,718
| +129% | +$40.6M | 0.03% | 599 |
|
|
2017
Q4 | $33.7M | Buy |
563,317
+156,249
| +38% | +$9.47M | 0.01% | 945 |
|
|
2017
Q3 | $19.8M | Buy |
407,068
+33,283
| +9% | +$1.82M | 0.01% | 1200 |
|
|
2017
Q2 | $19.6M | Buy |
373,785
+66,446
| +22% | +$3.09M | 0.01% | 1202 |
|
|
2017
Q1 | $13.9M | Buy |
307,339
+245,833
| +400% | +$11M | ﹤0.01% | 1362 |
|
|
2016
Q4 | $2.33M | Buy |
+61,506
| New | +$2.33M | ﹤0.01% | 2473 |
|
|
2016
Q2 | – | Sell |
-113,198
| Closed | -$1.38M | – | 3737 |
|
|
2016
Q1 | $1.38M | Sell |
113,198
-119,099
| -51% | -$1.88M | ﹤0.01% | 2713 |
|
|
2015
Q4 | $5.66M | Buy |
232,297
+14,320
| +7% | +$334K | ﹤0.01% | 1819 |
|
|
2015
Q3 | $3.87M | Buy |
217,977
+211,438
| +3,233% | +$3.83M | ﹤0.01% | 2054 |
|
|
2015
Q2 | $115K | Buy |
+6,539
| New | +$120K | ﹤0.01% | 3833 |
|
Invesco's AERI Position: Q4 2022 in Review
Invesco sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 21,023 shares — an estimated $318K sold.
Invesco first reported a position in AERI in Q2 2015 and held it in 27 quarters. The position peaked at $84.5M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Invesco reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Invesco sold 21,023 Aerie Pharmaceuticals shares in Q4 2022, an estimated $318K.
- Invesco first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 27 quarters.
- Invesco's Aerie Pharmaceuticals position peaked at $84.5M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Invesco's 13F filing for Q4 2022, filed 13 Feb 2023.